Bayer & Janssen v. Dr. Reddy’s: XARELTO® 2.5 mg Patent Dispute Dismissed With Prejudice
Bayer AG and Janssen Pharmaceuticals filed suit in the Delaware District Court against Dr. Reddy’s Laboratories over US10828310B2, a patent covering the 2.5 mg tablet strength of XARELTO® (rivaroxaban). After 1,674 days of litigation, all parties stipulated to dismissal with prejudice — each side bearing its own costs and attorneys’ fees.
ANDA pharma war ends after 4.6 years — no merits ruling, no cost award
In May 2021, Bayer AG and Janssen Pharmaceuticals, Inc. initiated an infringement action in the U.S. District Court for the District of Delaware against Dr. Reddy’s Laboratories, Inc. and Dr. Reddy’s Laboratories, Ltd. The dispute centred on US10828310B2 — a patent directed to the 2.5 mg tablet strength of XARELTO® (rivaroxaban) — and Dr. Reddy’s proposed generic equivalent. The case was presided over by Judge Richard G. Andrews, a highly experienced patent jurist in one of the busiest patent dockets in the United States.
The litigation concluded on 23 December 2025 via a joint stipulation under Federal Rules of Civil Procedure 41(a)(1) and 41(c). All claims asserted by plaintiffs against Dr. Reddy’s, and all counterclaims and defenses asserted by Dr. Reddy’s against plaintiffs, were dismissed with prejudice. Critically, each party agreed to bear its own costs, disbursements, and attorneys’ fees — a symmetrical cost allocation that strongly suggests the resolution reflected a negotiated commercial outcome rather than a concession by either side.
A 1,674-day duration is notable even for complex ANDA pharmaceutical patent litigation, and the with-prejudice dismissal — without any public merits ruling — is consistent with a confidential settlement or a licensing arrangement reached late in the case. The public record does not disclose specific settlement terms, any licence granted to Dr. Reddy’s, or any agreed market-entry date for the generic product. What is clear is that no court adjudicated the validity or infringement of US10828310B2, leaving the patent’s enforceability record formally intact.
Filing to Dismissed with Prejudice in 1674 days
1,674 days from filing to dismissal — roughly 4.6 years, above the median ANDA pharma case in D. Del.
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41 dismissal with prejudice — a permanent, bilateral bar
Under FRCP 41(a)(1) and 41(c), the parties jointly stipulated to dismiss all claims and all counterclaims with prejudice. ‘With prejudice’ means neither side may relitigate the same claims in any future federal action. This is the functional equivalent of a final judgment on the merits for preclusion purposes, even though no court ever ruled on the substance of infringement or validity.
No merits adjudicationPatent survives unchallenged — enforceability record preserved
Because the court never ruled on validity or infringement, US10828310B2 exits this litigation with no adverse finding on its record. Bayer and Janssen retain full enforcement rights against other potential generic entrants. The with-prejudice structure prevents Dr. Reddy’s from re-filing the same invalidity counterclaims, providing meaningful finality. The mutual cost allocation suggests neither side conceded a weak position.
Patent intact, enforcement rights preservedDr. Reddy’s: no invalidity win, but future market entry not publicly foreclosed
Dr. Reddy’s did not obtain a court ruling of non-infringement or invalidity that would clear a path to immediate generic entry. However, the dismissal with prejudice of plaintiffs’ infringement claims — coupled with the mutual cost structure — is consistent with a confidential agreement that may include a negotiated market-entry date or licence. The public record does not confirm or deny these arrangements.
No invalidity ruling obtainedXARELTO® 2.5 mg generic entry timeline remains opaque for the market
The absence of a public consent judgment or agreed entry date leaves market participants — including other generic manufacturers and payers — without a clear signal on when 2.5 mg rivaroxaban generics may launch. Other ANDA filers against the same patent face a landscape in which US10828310B2 has never been adjudicated, and the brand-side enforcement posture remains formally strong. Monitoring subsequent FDA Orange Book patent certifications and any new infringement filings by Bayer/Janssen will be critical.
Generic entry date undisclosedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bayer AG | Company | Pharmaceutical innovators and co-holders of US10828310B2 covering XARELTO® rivaroxabanSearch in Eureka ↗ |
| Co-Plaintiff | Janssen Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Bayer AG | Company | Search in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Indian multinational generic pharmaceutical manufacturer and its U.S. subsidiary seeking to market 2.5 mg rivaroxaban tabletsSearch in Eureka ↗ |
| Co-Defendant | Dr. Reddy’s Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Rodger Dallery Smith , II | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Bayer AGSearch in Eureka ↗ |
| Defendant counsel | Anandita Vyakarnam | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Eve H. Ormerod | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Neal C. Belgam | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Smith, Katzenstein, & Jenkins LLP | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation invokes both Rule 41(a)(1) — governing voluntary dismissal of claims — and Rule 41(c), which extends the same framework to counterclaims. The with-prejudice designation is legally significant: it operates as a final judgment on the merits for claim-preclusion purposes, meaning neither party may resurrect these specific claims in future federal litigation. The mutual cost-bearing clause is a marker of a negotiated exit rather than a capitulation, though the stipulation’s text is silent on any underlying commercial terms.
US10828310B2 — XARELTO® 2.5 mg rivaroxaban tablet formulation
US10828310B2, filed under application number US16/264032, is directed to the 2.5 mg tablet strength of rivaroxaban — the active ingredient in XARELTO®, a Factor Xa inhibitor indicated for reducing cardiovascular risk in patients with coronary artery disease and peripheral artery disease. This lower-dose formulation is distinct from the higher doses used in anticoagulation therapy and represents a commercially significant dosage form with its own regulatory and patent profile. The patent’s B2 designation indicates it issued following grant with reexamination or post-grant proceedings.
For the pharmaceutical sector, US10828310B2 represents one layer of the broader XARELTO® patent estate protecting a blockbuster cardiovascular franchise. The 2.5 mg indication targets a large and growing population of atherosclerosis patients, making generic entry commercially material. Any company holding an approved or pending ANDA for 2.5 mg rivaroxaban tablets — or any formulation scientist developing Factor Xa inhibitor combinations — should treat this patent as a critical FTO checkpoint, particularly given that its validity was never adjudicated in this proceeding.
Should your team run an FTO analysis against US10828310B2?
Any pharmaceutical company, contract manufacturer, or formulation-stage biotech working on rivaroxaban tablets — or Factor Xa inhibitor oral solid dosage forms more broadly — should conduct a formal freedom-to-operate analysis against US10828310B2 before committing to development or filing an ANDA. Because this patent was never invalidated or found non-infringed in the Dr. Reddy’s litigation, it carries no adverse public record that downstream developers can rely on for clearance.
PatSnap Eureka’s FTO Search Agent allows IP teams to map the full claim landscape of US10828310B2 against your product specifications, identify prior art that could support a validity challenge, and surface related continuation or divisional applications in the XARELTO® patent family. Eureka also monitors new Orange Book listings and litigation filings in real time, so your team receives early warning if Bayer or Janssen initiate enforcement actions against your ANDA or product launch.
Run a freedom-to-operate analysis on US10828310B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA rivaroxaban & cardiovascular pharma patent cases in D. Del.
Cases involving XARELTO®, rivaroxaban formulation patents, or ANDA infringement actions against Factor Xa inhibitor drugs litigated in the Delaware District Court.
What this case signals for the rivaroxaban and ANDA pharma IP landscape
A 4.6-year dispute ending in mutual with-prejudice dismissal carries important signals for generic pharma strategy and brand IP enforcement.
With-prejudice dismissals without cost awards typically indicate settlement
When both sides walk away bearing their own costs in a complex ANDA case of this duration, it strongly suggests a negotiated resolution. Brand companies rarely concede with prejudice without receiving something in return — typically a delayed entry date or market exclusivity window. Generic companies rarely accept with-prejudice dismissal without securing some form of commercial certainty.
US10828310B2 has no adverse validity ruling — enforcement posture is intact
Patent holders and their licensees should note that US10828310B2 emerged from this litigation without any court-issued invalidity or non-infringement finding. Any subsequent ANDA filer challenging this patent starts without the benefit of Dr. Reddy’s prior art arguments having been adjudicated, meaning the patent’s legal strength is formally untested.
Bayer v Dr. — key questions answered
The case was dismissed with prejudice on 23 December 2025 by joint stipulation under FRCP 41(a)(1) and 41(c). All claims and counterclaims were extinguished permanently. Each party agreed to bear its own costs, attorneys’ fees, and disbursements. No court ruling on infringement or validity of US10828310B2 was issued.
The patent at issue is US10828310B2, filed under application number US16/264032. It covers the 2.5 mg tablet strength of rivaroxaban, marketed by Bayer and Janssen as XARELTO®. The product at issue in this ANDA dispute was Dr. Reddy’s proposed 2.5 mg rivaroxaban generic tablet.
Not necessarily. A dismissal with prejudice extinguishes the specific litigation claims but does not itself grant market-entry rights. Any authorisation for Dr. Reddy’s to launch a generic would depend on FDA approval and any confidential settlement terms — which are not disclosed in the public court record. Other XARELTO® patents may also be relevant to Dr. Reddy’s launch timeline.
In U.S. patent litigation, fee-shifting to the losing party is possible under 35 U.S.C. § 285 in exceptional cases. When parties agree each side bears its own costs, it typically signals a negotiated resolution rather than an outright win for either side, and avoids any satellite litigation over fee awards. It is a common feature of confidential ANDA settlements.
Yes. Because the court never ruled on validity or infringement, US10828310B2 carries no adverse judicial finding. The patent remains formally enforceable, and Bayer and Janssen retain the right to assert it against other ANDA filers or generic manufacturers. Companies considering a Paragraph IV certification against this patent should conduct independent FTO and validity analysis.
PatSnap Eureka searches patents and litigation data to answer instantly.